Changes in Hong Kong stocks | Ruibo Bio-B (06938) rose more than 5% in the intraday period. The company submitted a phase I clinical application for RBD3133 injection in the European Union

The Zhitong Finance App learned that Ruibo Biotech B (06938) rose more than 5% intraday. As of press release, it rose 3.64% to HK$55.55, with a turnover of HK$14.7097 million.

According to the news, Ruibo Biotech announced that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union to treat overweight and obesity. This trial will provide the first evaluation of RBD3133 in humans and will lay the foundation for further clinical development.

RBD3133 is a key milestone in the company's siRNA product development portfolio in the field of cardiovascular and metabolic diseases, and is expected to become a cornerstone drug for the treatment of cardiovascular and metabolic diseases related to weight loss. As the company's first drug candidate in the field of obesity treatment, RBD3133 reflects the company's strategic focus on developing innovative drugs for a large group of patients with significant unmet medical needs.